ΠΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ ΠΈΡ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
ΠΠ°ΡΡΠ½Π°Ρ Π½ΠΎΠ²ΠΈΠ·Π½Π°. ΠΠΏΠ΅ΡΠ²ΡΠ΅ Π±ΡΠ»Π° ΠΈΠ·ΡΡΠ΅Π½Π° ΡΠ°ΡΡΠΎΡΠ° ΠΌΡΡΠ°ΡΠΈΠΉ Π³Π΅Π½Π° EGFR Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠΎΠΉ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ Π² Π‘Π΅Π²Π΅ΡΠΎ-ΠΠ°ΠΏΠ°Π΄Π½ΠΎΠΉ ΡΠ°ΡΡΠΈ Π Π€. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ Π½Π°Π»ΠΈΡΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΉ Ρ ΠΊΡΡΠ΅Π½ΠΈΠ΅ΠΌ Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅ ΠΈ ΠΏΠΎΠ»ΠΎΠΌ Π±ΠΎΠ»ΡΠ½ΡΡ . ΠΡΠ΅Π½Π΅Π½Π° ΡΠ°ΡΡΠΎΡΠ° ΠΎΠ±ΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ ΡΡΡΠ΅ΠΊΡΠΎΠ², ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΎ Π²ΡΠ΅ΠΌΡ Π΄ΠΎ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΎΠΏΡΡ ΠΎΠ»ΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΠ±ΡΠ°Ρ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ , ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ Π³Π΅ΡΠΈΡΠΈΠ½ΠΈΠ± Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠ΅ΡΠ²ΠΎΠΉ Π»ΠΈΠ½ΠΈΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π°… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠΊΡΠ΅Π»Ρ Π.Π., ΠΠ°Π²ΡΠ΄ΠΎΠ² Π. Π. Π‘ΡΠ°ΡΠΈΡΡΠΈΠΊΠ° Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π² Π ΠΎΡΡΠΈΠΈ ΠΈ ΡΡΡΠ°Π½Π°Ρ Π‘ΠΠ Π² 2005 Π³. // ΠΠ΅ΡΡΠ½ΠΈΠΊ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠ³ΠΎ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅Π½ΡΡΠ° ΠΈΠΌ. Π. Π. ΠΠ»ΠΎΡ ΠΈΠ½Π° Π ΠΠΠ, — 2007.Π’.-18, № 2.
- Π§ΠΈΡΡΠΎΠ² Π.Π., Π‘ΡΠ°ΡΠΈΠ½ΡΠΊΠΈΠΉ Π. Π., ΠΠ΅ΡΡΠΎΠ²Π° Π. Π. ΠΠ»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π² Π ΠΎΡΡΠΈΠΈ Π² 2005 Π³ΠΎΠ΄Ρ (Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡ ΠΈ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΡ) // Π€ΠΠ£ ΠΠΠΠΠ ΠΈΠΌ. Π. Π. ΠΠ΅ΡΡΠ΅Π½Π°.-2007. Π‘.252−254.
- Aifa S., Rebai A. ErbB antagonists patenting: «playing chess with cancer» // Recent Pat Biotechnol.-2008.-Vol. 2.-P. 181−187.
- Ardizzoni A., Boni L., Tiseo M. et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis // J Natl Cancer Inst.-2007.-Vol. 99.-P. 847−857.
- Arteaga C.L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia // J Clin Oncol.-2001.-Vol. 19.-P. 32S-40S.
- Asahina H., Yamazaki K., Kinoshita I. et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations // Br J Cancer.-2006.-Vol. 95.-P. 998−1004.
- Belani C.P., Schreeder M.T., Steis R.G. et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study// Cancer.-2008.-Vol. 113.-P. 2512−2517.
- Bepler G., Begum M., Simon G.R. Molecular analysis-based treatment strategies for non-small cell lung cancer // Cancer Control.— 2008-Vol. 15.-P. 130−139.
- Bepler G., Gautam A., Mcintyre L.M. et al. Prognostic significance of molecular genetic aberrations on chromosome segment1. lpl5.5 in non-small-cell lung cancer // J Clin Oncol.-2002.-Vol. 20.-P. 1353−1360.
- Boccaccio C., Comoglio P.M. Invasive growth: a MET-driven genetic programme for cancer and stem cells // Nat Rev Cancer.-2006.-Vol. 6.-P. 637−645.
- Bogdan S., Klambt C. Epidermal growth factor receptor signaling. //Curr Biol.-2001.-Vol. 11.-P. R292−5.
- Bunn P.A., Jr. Thatcher N. Systemic treatment for advanced (stage IHb/IV) non-small cell lung cancer: more treatment options- more things to consider. Conclusion // Oncologist.-2008.-Vol. 13 Suppl l.-P. 37−46.
- Cheng Y.W., Hsieh L.L., Lin P.P. et al. Gender difference in DNA adduct levels among nonsmoking lung cancer patients // Environ Mol Mutagen.-2001.-Vol. 37.-P. 304−310.
- Chiu C.H., Tsai C.M., Chen Y.M. et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity // Lung Cancer.-2005.-Vol. 47.-P. 129−138.
- Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level // Nat Rev Mol Cell Biol.-2006.-Vol. 7.-P. 505−516.
- Cobo M., Isla D., Massuti B. et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer // J Clin Oncol.-2007.-Vol. 25.-P. 2747−2754.
- Cortes-Funes H., Gomez C., Rosell R. et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients // Ann Oncol.-2005.-Vol. 16.-P. 10 811 086.
- Costa D.B., Kobayashi S., Tenen D.G. et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers // Lung Cancer.-2007.-Vol. 58.-P. 95−103.
- De Laat W.L., Jaspers N.G., Hoeijmakers J.H. Molecular mechanism of nucleotide excision repair // Genes Dev.-1999.-Vol. 13.-P. 768−785.
- Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia // Blood.-2005.-Vol. 105.-P. 2640−2653.
- Engelman J.A., Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer // Clin Cancer Res.-2008.-Vol. 14.-P. 2895−2899.
- Felip E., Rojo F., Reck M et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy // Clin Cancer Res.-2008.-Vol. 14.-P. 3867−3874.
- Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor // Endocr Rev.-1997.-Vol. 18.-P. 4−25.
- Fukuoka M., Yano S., Giaccone G. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) corrected. // J Clin 0ncol.-2003.-vol. 21.-P. 2237−2246.
- Furge K.A., Zhang Y.W., Vande Woude G.F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins // 0ncogene.-2000.-Vol. 19.-P. 5582−5589.
- Giaccone G., Hcrbst R.S., Manegold C. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1 // J Clin Oncol.-2004.-Vol. 22.-P. 777−784.
- Greulich H., Chen Π’.Π., Feng W. et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants // PLoS Med.-2005.-Vol. 2.-P. e313.
- Hanagiri Π’., Sugio K., Uramoto H. et al. Gender difference as a prognostic factor in patients undergoing resection of non-small cell lung cancer// Surg Today.-2007.-Vol. 37.-P. 546−551.
- Hanahan D., Weinberg R.A. The hallmarks of cancer // Cell.-2000-Vol. 100.-P. 57−70.
- Herbst R.S., Giaccone G., Schiller J.H. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial INTACT 2 // J Clin Oncol.-2004.-Vol. 22.-P. 785−794.
- Herbst R.S., Prager D., Hermann R. et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer // J Clin Oncol.-2005.-Vol. 23.-P. 5892−5899.
- Hida Π’., Ogawa S., Park J.C. et al. Gefitinib for the treatment of non-small-cell lung cancer // Expert Rev Anticancer Ther.-2009.-Vol. 9.-P. 17−35.
- Hidalgo M., Siu L.L., Nemunaitis J. et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies // J Clin 0ncol.-2001.-vol. 19.-P. 3267−3279.
- Hubbard S.R., Miller W.T. Receptor tyrosine kinases: mechanisms of activation and signaling // Curr Opin Cell Biol.-2007.-Vol. 19.-P. 117−123.
- Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors // Nat Rev Cancer.-2005.-Vol. 5.-P. 341−354.
- Hynes N.E., Macdonald G. ErbB receptors and signaling pathways in cancer I/ Curr Opin Cell Biol.-2009.-Vol. 21(2).-P. 177−84.
- Imyanitov E.N., Grigoriev M.Y., Gorodinskaya V.M. et al. Partial restoration of degraded DNA from archival paraffin-embedded tissues // Biotechniques.-2001.-Vol. 31.-P. 1000−1002.
- Inoue A., Kobayashi K., Usui K. et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermalgrowth factor receptor mutations without indication for chemotherapy // J Clin Oncol.-2009.-Vol. 27.-P. 1394−1400.
- Katzel J.A., Fanucchi M.P., Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer // J- Hematol Oncol.-2009.-Vol. 2.-P. 2.
- King L.E. Jr., Gates R.E., Stoscheck C.M. et al. The EGF/TGF alpha receptor in skin // J Invest Dermatol.-1990.-Vol. 94.-P. 164−170.
- Kobayashi S., Boggon T.J., Dayaram T. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib // N Engl J Med.-2005.-Vol. 352.-P. 786−792.
- Kosaka Π’., Yatabe Y., Endoh H. et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. // Cancer Res.-2004.-Vol. 64.-P. 8919−8923.
- Kosaka Π’., Yatabe Y., Endoh H. et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib // Clin Cancer Res.-2006.-Vol. 12.-P. 5764−5769.
- Kris M.G., Natale R.B., Herbst R.S. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial // JAMA.-2003.-Vol. 290.-P. 2149−2158.
- Langer C.J. The «lazarus response» in treatment-naive, poor performance status patients with non-small-cell lung cancer andepidermal growth factor receptor mutation // J Clin Oncol.—2009.-Vol. 27.-P. 1350−1354.
- Larminat F., Bohr V.A. Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage // Nucleic Acids Res.-1994.-Vol. 22.-P. 3005−3010.
- Li Π’., Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors // Target Oncol.-2009.-Vol.
- Lopez-Albaitero A., Ferris R.L. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer // Arch Otolaryngol Head Neck Surg.-2007-Vol. 133.-P. 1277−1281.
- Lynch T.J., Bell D.W., Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib // N Engl J Med.-2004.-Vol. 350.-P. 2129−2139.
- ΠΠΎΠΊ T.S., Wu Y.L., Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma // N Engl J Med.-2009.-Vol. 361.-P. 947−957.
- Nakagawa M., Nishimura Π’., Teramukai S. et al. Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer a retrospective analysis: JMTO LC03−02 // BMC Res Notes.-2009.-Vol. 2.-P. 157.
- National Cancer Institute: Common Terminology Criteria for Adverse Events (version 3).
- Group Non-Small Cell Lung Cancer Collaborative. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data onindividual patients from 52 randomised clinical trials // BMJ.-1995.-Vol. 311.-P. 899−909.
- Nose N., Sugio K., Oyama T. et al. Association between estrogen receptor—beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung // J Clin Oncol.-2009.-Vol. 27.-P. 411−417.
- O’byrne K.J., Koukourakis M.I., Giatromanolaki A. et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small—cell lung cancer // Br J Cancer.-2000.-Vol. 82.-P. 1427−1432.
- Olayioye M.A., Neve R.M., Lane H.A. et al. The ErbB signaling network: receptor heterodimerization in development and cancer // EMBO J.-2000.-Vol. 19.-P. 3159−3167.
- Omoto Y., Kobayashi Y., Nishida K. et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers // Biochem Biophys Res Commun.-2001.-Vol. 285.-P. 340−347.
- Paez J.G., Janne P.A., Lee J.C. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy // Science.-2004.-Vol. 304.-P. 1497−1500.
- Pao W., Miller V., Zakowski M. et al. EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib // Proc Natl Acad Sci U S A.-2004.-Vol. 101.-P. 13 306−13 311.
- Patrone C., Cassel T.N., Pettersson K. et al. Regulation of postnatal lung development and homeostasis by estrogen receptor beta // Mol Cell Biol.-2003.-Vol. 23.-P. 8542−8552.
- Perez-Soler R., Saltz L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining? // J Clin Oncol.-2005.-Vol. 23.—P. 5235−5246.
- Pirker R., Pereira J.R., Szczesna A. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer
- FLEX): an open-label randomised phase III trial // Lancet.-2009.-Vol. 373.-P. 1525−1531.
- Pitterle D.M., Kim Y.C., Jolicoeur E.M. et al. Lung cancer and the human gene for ribonucleotide reductase subunit Ml (RRM1) // Mamm Genome.-1999.-Vol. 10.-P. 916−922.
- Poon R.T., Fan S.T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients // J Clin Oncol.-2001.-Vol. 19.-P. 1207−1225.
- Rapp E., Pater J.L., Willan A. et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer—report of a Canadian multicenter randomized trial // J Clin Oncol.-1988.-Vol. 6.-P. 633−641.
- Reck M., Von Pawel J., Zatloukal P. et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil // J Clin Oncol.-2009.-Vol. 27.-P. 1227−1234.
- Robert F., Ezekiel M.P., Spencer S.A. et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer // J Clin Oncol.-2001.-Vol. 19.-P. 3234−3243.
- Roberts J.J., Thomson A.J. The mechanism of action of antitumor platinum compounds // Prog Nucleic Acid Res Mol Biol.-1979.-Vol. 22.-P. 71−133.
- Sandler A., Gray R., Perry M.C. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. // N Engl J Med.-2006.-Vol. 355.-P. 2542−2550.
- Sandler Π.Π., Johnson D.H., Herbst R.S. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer // Clin Cancer Res.-2004.-Yol. 10.-P. 4258s-4262s.
- Scagliotti G.V., Kortsik C., Dark G.G. et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial // Clin Cancer Res.-2005.-Yol. 11.-P. 690−696.
- Schiller J.H., Harrington D., Belani C.P. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer // N Engl J Med.-2002.-Vol. 346.-P. 92−98.
- Segaert S., Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors//Ann Oncol.-2005.-Yol. 16.-P. 1425−1433.
- Sequist L.Y., Bell D.W., Lynch T.J. et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer // J Clin Oncol.-2007.-Vol. 25.-P. 587−595.
- Sequist L.Y., Martins R.G., Spigel D. et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations // J Clin Oncol.-2008.-Yol. 26.-P. 2442−2449.
- Simon G., Sharma A., Li X. et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer // J Clin Oncol.-2007.-Vol. 25.-P. 2741−2746.
- Simon R. Designs for efficient clinical trials // Oncology (Williston Park).-1989.-Vol. 3.-P. 43−9- discussion 51−3.
- Skov B.G., Fischer B.M., Pappot H. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival // Lung Cancer.-2008.-Vol. 59.-P. 88−94.
- Stinchcombe Π’.Π., Socinski M.A. Current treatments for advanced stage non-small cell lung cancer // Proc Am Thorac Soc.-2009.-Vol. 6.-P. 233−241.
- Sugio K., Uramoto H., Ono K. et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking // Br J Cancer.-2006.-Vol. 94.-P. 896−903.
- Thatcher N. First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view // BMC Proc.— 2008 -Vol. 2 Suppl 2.-P. S3.
- Tokumo M., Toyooka S., Kiura K. et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers // Clin Cancer Res.-2005.-Vol. 11.-P. 1167−1173.
- Toyooka S., Matsuo K., Shigematsu H. et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer // Clin Cancer Res.-2007.-Vol. 13.-P. 5763−5768.
- Traynor A.M., Schiller J.H., Stabile L.P. et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer // Lung Cancer.-2009.-Vol. 64.-P. 51−60.
- Vilmar A., Sorensen J.B. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature //Lung Cancer.-2009.-Vol. 64.-P. 131−139.
- Walch A., Specht K., Smida J. et al. Tissue microdissection techniques in quantitative genome and gene expression analyses // Histochem Cell Biol.-2001.-Vol. 115.-P. 269−276.
- Weaver D.A., Crawford E.L., Warner K.A. et al. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines // Mol Cancer.-2005.-Vol. 4.-P. 18.
- West H.L., Franklin W.A., Mccoy J. et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126 // J Clin Oncol.-2006.-Vol. 24.-P. 1807−1813.
- Yamamoto H., Toyooka S., Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer // Lung Cancer.-2009.-Vol. 63.-P. 315−321.
- Zhang G., Liu X., Farkas A.M. et al. Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells // Mol Endocrinol.-2009.-Vol. 23.-P. 146−156.